CompletedPhase 2

Sildenafil for Treatment of Choroidal Ischemia

United States22 participantsStarted 2014-11-11

Plain-language summary

The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of retinal and choroidal degenerations (reticular or vitelliform AMD or vitelliform-type subretinal drusen) or hereditary or acquired retinal dystrophies (retinitis pigmentosa or central serous retinopathy) Exclusion Criteria: * Diagnosis of heart disease requiring use of nitrates * Inability to be examined monthly or bi-monthly

What they're measuring

Change in Visual Acuity (Sildenafil Group)

Timeframe: Up to 63 months

Change in Visual Acuity (Medical Record Review Group)

Timeframe: 22 months

Trial details

NCT IDNCT04356716

SponsorColumbia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-02-18

Results submitted2025-06-12

View on ClinicalTrials.gov More Choroidal Ischemia trials